Tempus AI, Inc. Faces Securities Lawsuit Over Misleading Statements
ByAinvest
Monday, Jul 14, 2025 4:04 am ET1min read
AZN--
The complaint, filed by Robbins Geller Rudman & Dowd LLP, claims that Tempus AI made false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the class period. Specifically, the lawsuit alleges that Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins, or were self-funded. It also alleges that the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation were at risk due to the appearance of "round-tripping" capital to create revenue. Additionally, the lawsuit claims that Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability.
The lawsuit further alleges that AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable "pass-through payment" via a joint agreement between it, Tempus AI, and Pathos AI, Inc. These issues revealed weakness in core operations and revenue prospects, according to the complaint.
The DJS Law Group, which also represents investors in the lawsuit, reminds shareholders that they have until August 12, 2025, to seek appointment as lead plaintiff. Investors who wish to participate should contact the firm before the deadline. The lead plaintiff will act on behalf of all other class members in directing the lawsuit.
Investors who purchased Tempus AI stock during the class period and suffered substantial losses are encouraged to contact Robbins Geller Rudman & Dowd LLP or the DJS Law Group to discuss their rights and potential claims. The law firms have extensive experience in securities fraud and shareholder litigation and have secured significant recoveries for investors in previous cases.
References:
[1] https://www.prnewswire.com/news-releases/tem-investor-deadline-robbins-geller-rudman--dowd-llp-announces-that-tempus-ai-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302500802.html
[2] https://www.easternprogress.com/tem-securities-lawsuit-filed-against-tempus-ai-inc-contact-the-djs-law-group-to-discuss/article_fd8a3de7-393f-5927-835b-4a27138d680d.html
[3] https://www.globenewswire.com/news-release/2025/07/10/3113549/34548/en/Deadline-Alert-Tempus-AI-Inc-TEM-Investors-Who-Lost-Money-Urged-To-Contact-Glancy-Prongay-Murray-LLP-About-Securities-Fraud-Lawsuit.html
TEM--
The DJS Law Group has filed a class action lawsuit against Tempus AI, Inc. for alleged violations of securities laws. The complaint claims that the company made false and misleading statements about agreements and transactions, including a joint venture with SoftBank and the acquisition of Ambry. Shareholders who purchased securities between August 6, 2024, and May 27, 2025, are encouraged to contact the firm before August 12, 2025.
Investors who purchased Tempus AI, Inc. (NASDAQ: TEM) stock between August 6, 2024, and May 27, 2025, are encouraged to participate in a class action lawsuit filed against the company. The lawsuit, captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), alleges violations of the Securities Exchange Act of 1934.The complaint, filed by Robbins Geller Rudman & Dowd LLP, claims that Tempus AI made false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the class period. Specifically, the lawsuit alleges that Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins, or were self-funded. It also alleges that the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation were at risk due to the appearance of "round-tripping" capital to create revenue. Additionally, the lawsuit claims that Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability.
The lawsuit further alleges that AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable "pass-through payment" via a joint agreement between it, Tempus AI, and Pathos AI, Inc. These issues revealed weakness in core operations and revenue prospects, according to the complaint.
The DJS Law Group, which also represents investors in the lawsuit, reminds shareholders that they have until August 12, 2025, to seek appointment as lead plaintiff. Investors who wish to participate should contact the firm before the deadline. The lead plaintiff will act on behalf of all other class members in directing the lawsuit.
Investors who purchased Tempus AI stock during the class period and suffered substantial losses are encouraged to contact Robbins Geller Rudman & Dowd LLP or the DJS Law Group to discuss their rights and potential claims. The law firms have extensive experience in securities fraud and shareholder litigation and have secured significant recoveries for investors in previous cases.
References:
[1] https://www.prnewswire.com/news-releases/tem-investor-deadline-robbins-geller-rudman--dowd-llp-announces-that-tempus-ai-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302500802.html
[2] https://www.easternprogress.com/tem-securities-lawsuit-filed-against-tempus-ai-inc-contact-the-djs-law-group-to-discuss/article_fd8a3de7-393f-5927-835b-4a27138d680d.html
[3] https://www.globenewswire.com/news-release/2025/07/10/3113549/34548/en/Deadline-Alert-Tempus-AI-Inc-TEM-Investors-Who-Lost-Money-Urged-To-Contact-Glancy-Prongay-Murray-LLP-About-Securities-Fraud-Lawsuit.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet